The concept that prostein IHC can be used to corroborate a suspected prostatic origin of a cancer tissue is further supported by the retained prostein expression in at least 80% of prostate cancers that recurred after hormonal therapy [19]. This evidence concerns the gene SLC45A3 and prostate carcinoma.